A few months after announcing an expansion of its strategic partnership with Mayo Clinic, the software company nference said that North Carolina-based Duke Health would leverage the company’s analytics platform to promote new scientific breakthroughs.
Cambridge, Mass.-based nference said its proprietary AI-enabled software platform, nSights, has been used to accelerate life sciences research, development, and clinical care, including biomarker discovery and validation, real-world evidence generation leveraging real-world data, early disease detection, public health policy generation and validation, and more.
The nSights platform provides a longitudinal, 360-degree view of each patient by leveraging an ensemble of biomedical information, such as electronic health records, electrocardiograms, radiology images and more. Future iterations will also include digital pathology and genomics.
The partnership with Mayo Clinic provides nference partners and customers with access to Mayo Clinic Platform’s de-identified electronic health data across a range of disease and therapeutic areas. The collaboration will establish a Mayo Clinic-branded version of nSights, called Mayo Clinic Platform Discover, built and supported by nference.
According to Jeffrey Ferranti, M.D., senior vice president and chief digital officer at Duke Health, the partnership will expand Duke’s research capabilities in health analytics science. In addition, it will fast-track our ability to usher in the next generation of evidence-based medicine. “The average time for life-saving research to get from the bench to bedside, and then to our communities, can take up to 17 years,” said Ferranti, in a statement. “During this time, many patients miss out on access to next-generation cures, and we have a responsibility to lead in bringing these cures to patients faster.”
“Duke is uniquely positioned to lead efforts in the discovery of new models for care, education, research, and innovation,” added Mary Klotman, M.D., dean of the Duke University School of Medicine, and vice chancellor for health affairs at Duke, in a statement. “Duke’s world-class faculty, supported by industry-leading technology, can expand research to further address our community’s most pressing health concerns and to eliminate health inequalities.”
Murali Aravamudan, co-founder and CEO of nference, called the partnership with Duke “a key milestone toward developing a unique federated network of leading academic medical centers that will accelerate research, drive new therapeutic and diagnostic discoveries, and fuel the creation of new ventures in global healthcare.”
